Susan J. McCall

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

Alison J. Moskowitz, Heiko Schöder, Joachim Yahalom et al. · The Lancet Oncology · 2015 · 266 citations

Medicine, Oncology, Pharmacology +17

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma

Alison J. Moskowitz, Heiko Schöder, Somali Gavane et al. · Blood · 2017 · 137 citations · Full text

Medicine, Clinical Sciences, Oncology +13

Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma

Paul J. Bröckelmann, Horst Müller, Olivier Casasnovas et al. · Annals of Oncology · 2017 · 93 citations · Full text

Medicine, Hematology, Oncology +16

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Anita Kumar, Carla Casulo, Joachim Yahalom et al. · Blood · 2016 · 77 citations · Full text

Medicine, Oncology, Radiation Oncology +14

A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL

Craig S. Sauter, Matthew J. Matasar, Heiko Schöder et al. · Blood · 2018 · 68 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +5